Indication
Stomach Adenocarcinoma
92 clinical trials
98 products
33 drugs
Product
ASKB589Clinical trial
A Phase III Study Evaluating the Efficacy and Safety of ASKB589 Combined With CAPOX and PD-1 Inhibitor as First-Line Treatment in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-12-30
Product
CapecitabineProduct
OxaliplatinProduct
TislelizumabProduct
PlaceboClinical trial
nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Product
Ramucirumab + PaclitaxelProduct
PembrolizumabProduct
IMU-131Clinical trial
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-25
Product
PY159Product
PY159/PembrolizumabClinical trial
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
DKN-01Product
LeucovorinProduct
FluorouracilClinical trial
A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 ExpressionStatus: Recruiting, Estimated PCD: 2026-06-30
Product
ASP2138Product
VLS-1488Clinical trial
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Product
PY159 PembrolizumabProduct
NM32-2668Clinical trial
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-12-31
Product
Leucovorin CalciumProduct
INBRX-105Product
JK08Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic CancerStatus: Recruiting, Estimated PCD: 2025-10-17
Product
DerazantinibClinical trial
A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic AberrationsStatus: Terminated, Estimated PCD: 2022-11-21
Product
Ramucirumab plus PaclitaxelProduct
TRK-950Product
RamucirumabClinical trial
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerStatus: Recruiting, Estimated PCD: 2025-08-31
Product
PaclitaxelClinical trial
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-11-28
Product
Ladiratuzumab vedotinProduct
pembrolizumabProduct
AK104Clinical trial
A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-08-18
Product
GentuximabClinical trial
A Randomized, Double-blind, Parallel Controlled Phase III Study of Gentuximab Injection Combined With Paclitaxel Injection Versus Placebo Combined With Paclitaxel Injection for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard TherapiesStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
TPST-1495Clinical trial
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Advanced Solid Tumors or AK104 in Combination With Oxaliplatin and Capecitabine As First-line Therapy in Subjects With Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced CancersStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TTI-101Product
tucatinibClinical trial
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)Status: Active (not recruiting), Estimated PCD: 2025-05-31
Product
paclitaxelClinical trial
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-05-01
Product
TaxotereProduct
EvorpaceptProduct
DocetaxelProduct
SKB264Product
trastuzumabProduct
ramucirumabProduct
RAIN-32Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106)Status: Terminated, Estimated PCD: 2023-02-12
Clinical trial
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus: Completed, Estimated PCD: 2019-03-26
Product
CisplatinProduct
5-FUClinical trial
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
SintilimabProduct
5-fluorouracilProduct
SL-279252Clinical trial
A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With CAPOX Chemotherapy Compared to Placebo in Combination With CAPOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ AdenocarcinomaStatus: Completed, Estimated PCD: 2023-07-09
Product
CS1001Clinical trial
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric MalignanciesStatus: Completed, Estimated PCD: 2019-07-19
Clinical trial
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) CancerStatus: Recruiting, Estimated PCD: 2027-10-31
Drug
AtezolizumabDrug
DocetaxelDrug
fluorouracilDrug
mFOLFOX6Product
CabozantinibClinical trial
Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC)Status: Active (not recruiting), Estimated PCD: 2023-11-25
Clinical trial
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)Status: Not yet recruiting, Estimated PCD: 2029-03-30
Product
Extended Dosing IntervalProduct
Standard of CareClinical trial
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid TumorsStatus: Recruiting, Estimated PCD: 2027-12-01
Product
KK2269Clinical trial
A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Nal-IRIDrug
TrastuzumabClinical trial
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaStatus: Completed, Estimated PCD: 2023-04-14
Drug
mFOLFOXIRIProduct
Blood for angiome profilingProduct
Blood for cfDNAProduct
NivolumabClinical trial
A Phase Ib Trial of Preoperative Short-Course Chemoradiotherapy Followed by Chemotherapy for Resectable Gastric AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2028-12-31
Clinical trial
Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II StudyStatus: Recruiting, Estimated PCD: 2028-09-01
Product
DostarlimabDrug
UTD1Clinical trial
A Phase II Trial of Neoadjuvant Pembrolizumab for Resectable Early Stage Gastroesophageal AdenocarcinomaStatus: Terminated, Estimated PCD: 2023-03-11
Clinical trial
A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard TherapyStatus: , Estimated PCD: 2024-07-01
Clinical trial
A Phase Ib Multicenter Study of TAS-102 in Combination With Irinotecan in Patients With Advanced Recurrent or Unresectable Gastric and Gastroesophageal Adenocarcinoma After at Least One Line of Treatment With a Fluoropyrimidine and Platinum Containing RegimenStatus: Completed, Estimated PCD: 2021-07-14
Drug
TAS-102Drug
IrinotecanClinical trial
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal AdenocarcinomasStatus: Completed, Estimated PCD: 2020-09-11
Drug
5 fluorouracilProduct
AvelumabClinical trial
A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab With Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric TumorsStatus: Recruiting, Estimated PCD: 2027-11-30
Clinical trial
Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at ProgressionStatus: Not yet recruiting, Estimated PCD: 2028-10-01
Clinical trial
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot StudyStatus: Recruiting, Estimated PCD: 2026-01-01
Product
AldesleukinDrug
5-FUDrug
CisplatinClinical trial
An Open-Label, Phase II Single-Arm, Window Trial of Tadalafil Effect + Chemotherapy in Patients With Resectable Gastric/GEJ AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
TadalafilClinical trial
Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual DiseaseStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Randomized Trial Comparing Early Local Chemoradiation Therapy +/- Surgery Versus Systemic Therapy for Patients With Esophageal or Gastric Cancer With OligometastasesStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
An Open, Multicenter, Phase II Study of Cadonilimab Combined With Paclitaxel (Albumin-bound) in the Treatment of Advanced Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma With PD-(L)1 Inhibitors ResistanceStatus: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal EffectStatus: Completed, Estimated PCD: 2022-01-20
Clinical trial
A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI CancersStatus: Recruiting, Estimated PCD: 2024-11-28
Clinical trial
Perioperative S-1 Plus Oxaliplatin Combined With Serplulimab or Placebo for Locally Advanced Gastric Adenocarcinoma With Proficient Mismatch Repair: a Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled StudyStatus: Recruiting, Estimated PCD: 2026-04-30
Drug
S1Clinical trial
A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-01-19
Drug
TAS 102Clinical trial
An Early Exploratory Clinical Trial of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma.Status: Recruiting, Estimated PCD: 2025-11-16
Clinical trial
A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal AdenocarcinomasStatus: Terminated, Estimated PCD: 2022-05-19
Product
Regorafenib and IrinotecanDrug
FOLFOXIRIProduct
SerplulimabDrug
VarlilumabClinical trial
A Phase II, Single Arm, Single Center Study of Cadonilimab(AK104) in Combination With Ivonescimab(AK112) Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced Gastric (G) or Gastroesophageal Junction (GEJ) CancerStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Drug
AK104Drug
IvonescimabDrug
XELOXDrug
SOXClinical trial
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Product
APL-5125Clinical trial
Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet ChemotherapyStatus: Recruiting, Estimated PCD: 2026-01-01
Product
Trifluridine/TipiracilProduct
FOLFOXDrug
T-VECClinical trial
A Phase Ib/II Study of Regorafenib and Nivolumab Plus Chemotherapy in Patients With Unresectable Advanced/Recurrent Gastric/Gastroesophageal Junction/Esophageal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
RegorafenibProduct
CapeOXClinical trial
Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Immunotherapy Refractory Esophagogastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-04-01
Product
OBP-301Clinical trial
Perioperative S-1 Plus Oxaliplatin Combined With Toripalimab or Toripalimab Monotherapy Versus S-1 Plus Oxaliplatin for Treatment of dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Randomized Controlled StudyStatus: Recruiting, Estimated PCD: 2026-02-28
Drug
PD-1 antibodyClinical trial
An Open-label, Single Center, Phase II Study of Surufatinib Combined With Sintilimab in Patients With Advanced Adenocarcinoma of the Gastric or Gastrooesophageal Junction Adneocarcinoma CancerStatus: Recruiting, Estimated PCD: 2024-03-31
Product
Surufatinib+SintilimabClinical trial
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive CytologyStatus: Recruiting, Estimated PCD: 2028-10-31
Drug
TiragolumabProduct
DexamethasoneClinical trial
Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired BiopsiesStatus: Completed, Estimated PCD: 2018-05-29
Product
EpacadostatProduct
DiphenhydramineProduct
FamotidineClinical trial
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With PembrolizumabStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.Status: Terminated, Estimated PCD: 2024-03-27
Product
Indocyanine greenClinical trial
Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)Status: Active (not recruiting), Estimated PCD: 2026-12-30
Drug
LurbinectedinClinical trial
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal CarcinomatosisStatus: Active (not recruiting), Estimated PCD: 2023-02-25
Clinical trial
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersStatus: Recruiting, Estimated PCD: 2025-03-31
Drug
mFOLFIRINOXDrug
pembrolizumabClinical trial
A Randomized, Open Labeled Phase II Pilot Study of Total Neoadjuvant Chemotherapy With FLOT ( FLOT-TNT) VS Standard Perioperative FLOT ( FLOTPOP) in Patients With Gastric or GEJ Cancer, and Assessment of CTDNA as Correlative Biological ResponseStatus: Recruiting, Estimated PCD: 2028-10-01
Product
GSCFClinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified CutoffStatus: Recruiting, Estimated PCD: 2025-09-30
Drug
SpartalizumabClinical trial
A Randomized Phase II Study Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-03-15
Drug
AN0025Product
TremelimumabProduct
FOLFIRIClinical trial
A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal AdenocarcinomaStatus: , Estimated PCD: 2015-03-06
Product
AMG 337Drug
oxaliplatinClinical trial
An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2023-06-30
Product
CT048Clinical trial
Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2026-07-28
Clinical trial
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal MalignanciesStatus: Completed, Estimated PCD: 2017-12-01
Product
IrinotecanClinical trial
PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-06-08
Clinical trial
A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Product
FLOTClinical trial
Pre-operative Adaptive Short Course Radiation Therapy in Gastric CancerStatus: Recruiting, Estimated PCD: 2026-04-30
Product
RucaparibClinical trial
A Pilot Study of Ramucirumab Beyond Progression Plus TAS-102 in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or the Gastroesophageal Junction, After Treatment Failure on a Ramucirumab Based TherapyStatus: Completed, Estimated PCD: 2022-01-13
Clinical trial
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal CytologyStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Sodium ThiosulfateClinical trial
The Study of Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Initial Unresectable Local Advanced or Potentially Resectable Metastatic Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Tucidinostat in Combination With PD-1 Inhibitor and Bevacizumab as Late-line Treatment in Patients With Advanced Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction and Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-12-01
Product
TucidinostatClinical trial
An Open Label Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsStatus: , Estimated PCD: 2024-12-01
Clinical trial
Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-03-01
Product
pabolizumabClinical trial
A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2032-04-30
Drug
MetforminProduct
RosiglitazoneClinical trial
GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.Status: Active (not recruiting), Estimated PCD: 2026-05-01
Product
HIPEC with oxaliplatinClinical trial
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasStatus: Recruiting, Estimated PCD: 2025-12-01
Product
INBRX-109Product
PemetrexedProduct
TMZClinical trial
Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic AnalysisStatus: Completed, Estimated PCD: 2021-12-01
Drug
pembrolizumabClinical trial
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-02-02
Product
Indocyanine GreenClinical trial
Sintilimab Combined With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherapy for Conversion Therapy in Unresectable Stage IV Gastric Cancer: a National Multicenter Randomized Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2026-06-01